HIV/AIDS
Conditions
Interventions
Event-driven intake group:Two tablets of truvada 2-24 hours before each sexual intercourse, followed by two single doses of truvada, 24 and 48 hours after the frst drug intake
Daily intake group:One tablet of truvada every 24 hours, orally
Sponsors
The First Affiliated Hospital, China Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years old; 2. Not infected with HIV-1 or HIV-2; 3. Participants of male sex at birth and who have sex with men, who in the 6 months. prior to screening report one or more of the following risk criteria: (1) Unprotected (condomless) receptive anal intercourse with one or more partners; (2) More than two male partners in the 6 months prior to enrolment (regardless of condom use and HIV serostatus, as reported by the enrolee). (3) Reported STI with syphilis, HSV-2gonorrhea, chlamydia, chancroid, or lymphogranuloma venereum; (4) Reported a history of Post-exposure prophylaxis(PEP). Note: Participants in a monogamous relationship with an HIV-1 seronegative partner or a virologically-suppressed HIV-1 + partner for > 1 year are not eligible for participation; 4. Through comprehensive physical examination (including a regular checkup, urinalysis, blood biotest, ECG, et al.). No serious liver or kidney dysfunction, negative HBs antigen and negative hepatitis C virus (HCV) serologyosteoporosisand other indicators are normal; 5. The subjects be able to fully understand the study objects, design and possible outcomes of the study, and volunteered to join and can provide signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Allergy physique or people who are allergic to the ingredients of the experiment drug and ART; (2) People who are suffering serious chronic diseases, metabolic diseases (such as diabetes), neurological and psychiatric disorders; (3) Individuals who are unsuitable for enrollment (such as illness, or have poor adherence); (4) Treatment with Interferon, Interleukin, or antiretrovirals.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HIV incidence; | — |
Secondary
| Measure | Time frame |
|---|---|
| syphilis incidence;HSV-2 incidence; | — |
Countries
China
Contacts
Public ContactHong Shang
Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University
Outcome results
None listed